United Kingdom

• GPhC-registered pharmacy premises plus a superintendent pharmacist. A non-pharmacist can own 100% of the corporate entity under Medicines Act 1968 s.69/71. The superintendent must be a real senior decision-maker with authority, not a nominal signature, the GPhC has sanctioned exactly that failure mode.
• CQC registration in England for the online prescribing service, under "treatment of disease, disorder or injury". CQC treats the separate "slimming clinic" activity as requiring a physical location, so remote services fall under the general activity.
• Scotland, Wales and Northern Ireland are genuinely unresolved for pure-online models. HIS's own guidance is written for face-to-face services and tells providers to email and ask. Budget for bespoke advice if you sell UK-wide.
• LegitScript certification: not legally required but functionally mandatory: Google recognised it as satisfying UK telemedicine advertiser certification in June 2025. Roughly $1.5–2k to apply, $3–4k in year-one fees, $8–20k all-in.

Human Medicines Regulations 2012, reg. 284: "A person may not publish an advertisement that is likely to lead to the use of a prescription only medicine." Reg. 303 makes breach an offence carrying, on indictment, "imprisonment for a term not exceeding two years." This is criminal law, not an ASA slap.

You may not name Mounjaro, Wegovy, Ozempic, semaglutide, tirzepatide or "GLP-1"; say "skinny jab" or "weight-loss injection"; show a pen, branded or unbranded; show prices, "from £139.50 per pen" has been ruled an implicit POM ad; run before/after content tied to treatment; or use influencers, discount codes or affiliate referral links.

You may advertise "a weight management service" or "doctor-led obesity treatment" generically, publish clinical information on inner pages not linked directly from ads, and market to healthcare professionals without any of these restrictions.

CAP's April 2026 enforcement report covers 95,000 unique ads monitored across Google, Meta and TikTok using AI scanning. The breach rate fell from 7% (Feb 2025) to 4% after the first joint MHRA/GPhC/ASA enforcement notice to 1% after the second. 44 advertisers across 38 organisations were identified; one was referred to the GPhC.

On 12 February 2026 the ASA banned 13 social posts promoting Voy, Zava, MedExpress and UK Meds Direct: discount codes, referral links, pen imagery, before/afters. Its finding on affiliates is unambiguous: "both the individual poster and the business can be held responsible." Voy was specifically ordered to police its own refer-a-friend scheme. In December 2025 the MHRA formally found against Menwell Ltd (trading as Voy) over a "£94 a month" headline that did not relate to the product advertised, and the ASA separately banned CheqUp and MedExpress ads on 17 December 2025 as "irresponsible" and "exploiting body image insecurities".

The February 2025 distance-selling guidance changed the product. The prescriber must independently verify the patient's height, weight and BMI, by a route other than the patient's own typing. Acceptable: video consultation, in person, clinical records, or contacting the GP. Explicitly not acceptable: a phone call alone ("would not be appropriate when supplying medication for weight loss"), or static photos and pre-recorded video for a first prescription.

Two further clauses matter commercially. Prescribing decisions may not rest on a questionnaire alone. And the pharmacy owner and superintendent remain "responsible for providing the pharmacy service safely and effectively even if… sub-contracted to a third party", you cannot outsource the liability. The GPhC also bans volume-linked incentives that could compromise patient safety, which rules out the commission structures a growth marketer reaches for first.

Its April 2026 review found concerns about pharmacies jumped from 208 in 2024 to 1,099 in 2025, 17% of them about advertising, specifically influencers and discount codes.

On 1 September 2025 Eli Lilly raised UK Mounjaro list prices by up to 170%: 2.5mg from £92 to £133, 15mg from £122 to £330. Retail did not follow all the way up, so at published list cost several doses are loss-making at market retail. One rebate data point is public, Lilly supplying 15mg at £247.50 rather than £330.

Lilly then suspended sales to UK wholesalers, and routed private Mounjaro through LillyDirect, initially via two named dispensing partners, Pharmacy2U and Blueco Healthcare. On 3 August 2026 eligibility opened to GPhC- and PSNI-regulated pharmacies running private weight-management services. Application terms, quotas and pricing are not public. That application is the cheapest kill-or-continue question in any UK plan.

The MHRA approved the Wegovy pill on 11 June 2026; it went on sale through private providers on 6 July 2026. Roughly 300,000 UK patients started in the first three weeks, and Wegovy's UK market share jumped from about 30% to 45%. Simple Online Healthcare reported a 55,000-strong waitlist.

The tablet stores at 20–25°C and must not be refrigerated. No ice packs, no insulated pouch, no next-day-only courier. That deletes the largest operating cost and risk in online GLP-1 dispensing, and with it, the fulfilment moat that protected incumbents. Prices start around £99 and top out near £189–£219, against £169–£339 for injectable Mounjaro.

Orforglipron (Foundayo) was authorised by the MHRA on 10 August 2026, the first approval in Europe, and launched around 23 August 2026. It is a small molecule, so structurally far cheaper to make than any semaglutide product.